Clinical Trial

Effects of Probiotic Oral Intake on Plasma Chlordecone (Kepone) Concentrations in Individuals Environmentally Exposed to Pesticide in Martinique.

Study acronym: CHLOR-DETOX
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 21, 2024 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The CHLOR-DETOX study is a single-centre, double-blind, prospective, interventional, controlled, exploratory pilot study on subjects environmentally exposed to the organochlorine pesticide (kepone or chlordecone, CLD) in the French Caribbean (Martinique island). To our best knowledge, it is the first clinical trial in such subjects evaluating the potential effect of oral probiotic intake (Limosilactobacillus reuteri) on the reduction of CLD plasma levels (chlordeconemia) and fecal excretion, thus concurring to the reduction of CLD toxicity in study subjects.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-30; most recent amendment 2024-02-19.
Trial Details
NCT Number NCT06026228
Lead Sponsor University Hospital Center of Martinique
Collaborators: BioGaia AB, University Hospital, Limoges, Regional Health Agency, Martinique, Biological Resource Centre, Martinique, Reims University hospital
Conditions Chlordecone (Kepone) Toxicity
Enrollment 100 participants
Start Date 2024-04
Primary Completion 2026-04 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2024-02-21